(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 7 April 2005 (07.04.2005)

(10) International Publication Number WO 2005/030761 A1

- (51) International Patent Classification7: C07D 409/12, 235/08, 413/12, 403/12, 401/04, 405/14, A61K 31/4184, A61P 25/00
- (21) International Application Number:

PCT/GB2004/004112

(22) International Filing Date:

24 September 2004 (24.09.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0302570-7

26 September 2003 (26.09.2003) SB

- (71) Applicant (for all designated States except MG, US): AS-TRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).
- (71) Applicant (for MG only): ASTRAZENECA UK LIM-ITED [GB/GB]; 15 Stanhope Gate, London Greater London W1K 1LN (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): LIU Ziping [CA/CA]; AstraZeneca R & D Montréal, 7171 Fredrick-Banting, St Laurent, Québec H4S 129 (CA). MILBURN, Claire [CA/CA]; AstraZeneca R & D Montréal, 7171 Fredrick-Banting, St Laurent, Québec H4S 129 (CA). PAGÉ, Daniel [CA/CA]; AstraZeneca R & D Montréal, 7171 Fredrick-Banting, St Laurent, Québec H4S 129 (CA). TREMBLAY, Maxime [CA/CA]; AstraZeneca R & D Montréal, 7171 Fredrick-Banting, St Laurent, Québec ning of each regular issue of the PCT Gazette.

H4S 129 (CA). WALPOLE, Christopher [GB/CA]; AstraZeneca R & D Montréal, 7171 Prederick-Banting, St Laurent, Québec H4S 129 (CA). YANG, Hua [CA/CA]; AstraZeneca R & D Montréal, 7171 Frederick-Banting, St Laurent, Québec H4S 1Z9 (CA).

- (74) Agent: GLOBAL INTELLECTUAL PROPERTY; AstraZeneca AB, S-151 85 Södertälje (SE).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN. CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Burasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the begin-

(54) Title: BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND **USES THEREOF**

$$(R^3)_n \longrightarrow Ar \stackrel{Q}{\stackrel{N}{\stackrel{N}{\longrightarrow}}} N \longrightarrow R^2 \qquad (I)$$

(57) Abstract: Compounds of Formula (I) or pharmaceutically acceptable salts thereof; wherein R1, R2, R3, R4, n and Ar are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

